TSHA

Taysha Gene Therapies Inc

TSHA, USA

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

https://www.tayshagtx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TSHA
stock
TSHA

Taysha Gene Therapies (NASDAQ:TSHA) Rating Increased to Hold at Wall Street Zen Defense World

Read more →
TSHA
stock
TSHA

Taysha Gene Therapies (TSHA) Is Up 13.8% After TSHA-102 Phase 3 Upgrade Momentum - Has The Bull Case Changed? simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$10.5385

Analyst Picks

Strong Buy

7

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

9.34

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-14.95 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-10.34 %

Low 2%

High 10%

Debt to Equity

-

High

0.45

Low 1

High 0.3

Investors

* Institutions hold a combined 95.37% of the total shares of Taysha Gene Therapies Inc

1.

RTW INVESTMENTS, LLC

(9.1723%)

since

2025/06/30

2.

RA Capital Management, LLC

(8.6349%)

since

2025/06/30

3.

venBio Select Advisor LLC

(7.9547%)

since

2025/06/30

4.

Morgan Stanley - Brokerage Accounts

(6.1823%)

since

2025/06/30

5.

FMR Inc

(5.7288%)

since

2025/06/30

6.

BlackRock Inc

(4.8768%)

since

2025/06/30

7.

Octagon Capital Advisors LP

(4.6161%)

since

2025/06/30

8.

Goldman Sachs Group Inc

(4.6143%)

since

2025/06/30

9.

Siren, L.L.C.

(4.0377%)

since

2025/06/30

10.

Vanguard Group Inc

(3.9935%)

since

2025/06/30

11.

Jefferies Financial Group Inc

(3.7808%)

since

2025/06/30

12.

Point72 Asset Management, L.P.

(2.6825%)

since

2025/06/30

13.

Vanguard Total Stock Mkt Idx Inv

(2.4315%)

since

2025/07/31

14.

Deerfield Management Co

(1.9744%)

since

2025/06/30

15.

Fidelity Growth Compy Commingled Pl S

(1.969%)

since

2025/07/31

16.

State Street Corp

(1.8836%)

since

2025/06/30

17.

Polar Capital Holdings PLC

(1.8329%)

since

2025/06/30

18.

Polar Capital Biotech S Inc

(1.8329%)

since

2025/07/31

19.

Adage Capital Partners Gp LLC

(1.7739%)

since

2025/06/30

20.

The Toronto-Dominion Bank

(1.7335%)

since

2025/06/30

21.

Fidelity Growth Company Fund

(1.5416%)

since

2025/07/31

22.

Tybourne Capital Management (HK) Ltd

(1.5011%)

since

2025/06/30

23.

iShares Russell 2000 ETF

(1.476%)

since

2025/08/31

24.

Baker Bros Advisors LP

(1.468%)

since

2025/06/30

25.

Geode Capital Management, LLC

(1.3906%)

since

2025/06/30

26.

Fidelity Select Biotechnology

(1.2679%)

since

2025/07/31

27.

Fidelity Small Cap Index

(0.6103%)

since

2025/06/30

28.

Vanguard Institutional Extnd Mkt Idx Tr

(0.5889%)

since

2025/07/31

29.

Fidelity Growth Company K6

(0.5559%)

since

2025/07/31

30.

iShares Russell 2000 Growth ETF

(0.5319%)

since

2025/08/31

31.

SPDR® S&P Biotech ETF

(0.5301%)

since

2025/08/31

32.

iShares Biotechnology ETF

(0.4699%)

since

2025/08/31

33.

Fidelity Series Growth Company

(0.3604%)

since

2025/07/31

34.

Fidelity Extended Market Index

(0.3005%)

since

2025/07/31

35.

Vanguard Russell 2000 ETF

(0.2894%)

since

2025/07/31

36.

State St Russell Sm Cap® Indx SL Cl I

(0.2118%)

since

2025/08/31

37.

Schwab Small Cap Index

(0.1528%)

since

2025/07/31

38.

NT R2000 Index Fund - NL

(0.147%)

since

2025/06/30

39.

iShares Micro-Cap ETF

(0.1376%)

since

2025/08/31

40.

Vanguard Health Care ETF

(0.1278%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.0976

Latest Release

Date

2025-09-30

EPS Actual

-0.0875

EPS Estimate

-0.08

EPS Difference

-0.0075

Surprise Percent

-9.375%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.